A recent announcement by logistics tech provider GetSwift that it will be relocating to Canada has heightened concerns by the lawyers running a shareholder class action against the company that it might not be able to meet any orders for compensation to group members.
App stores have become the latest battleground in the the Australian Competition and Consumer Commission’s investigation into digital platforms, with the regulator promising to look at data sharing practices, pricing and competition between Google and Apple, the two biggest players in the market.
A seven-week trial in ASIC’s misleading conduct case against Rio Tinto may have to be postponed after two executives of the mining giant raised concerns that COVID-19 could impact their ability to appear as defendants in the case.
An appeals court has dealt with complex jurisdiction and limitations issues in transferring one of three class actions against ride sharing giant Uber to another court, with one of the judges saying legislative reforms were needed to deal with the issues.
The judge overseeing professional misconduct claims against lawyers in the Banksia class action has denied a recusal application brought by Alex Elliott, the son of deceased class action lawyer Mark Elliott, who was joined to the proceedings in August.
An IOOF subsidiary sued over “bad advice” has failed in its bid to stop ASIC from using documents from the banking royal commission as evidence in the case, with a judge saying the company had already provided the material to the financial watchdog without objection.
A former Piper Alderman partner has lost her bid to bring sex discrimination claims against the partners of the law firm, but can still proceed with her other claims.
Mining giant BHP is seeking to have foreign group members shut out of a shareholder class action over the Fundao dam failure in Brazil five years ago.
Mayfair director James Mawhinney has been blocked from talking to investors ahead of a hearing on an application to wind up the IPO Wealth fund, after a judge raised concerns about investors being “misled and coerced” by the investment hotshot.
US pharmaceutical giant Merck Sharp & Dohme has taken a unit of Indian generic manufacturer Lupin to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Januvia and Janumet.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
